Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lori, Christman"'
Autor:
Milan T. Makale, Shaghayegh Abbasi, Chad Nybo, Jason Keifer, Lori Christman, J. Kaci Fairchild, Jerome Yesavage, Kenneth Blum, Mark S. Gold, David Baron, Jean Lud Cadet, Igor Elman, Catherine A. Dennen, Kevin T. Murphy
Publikováno v:
Heliyon, Vol 9, Iss 8, Pp e18943- (2023)
Emerging data suggest that post-traumatic stress disorder (PTSD) arises from disrupted brain default mode network (DMN) activity manifested by dysregulated encephalogram (EEG) alpha oscillations. Hence, we pursued the treatment of combat veterans wit
Externí odkaz:
https://doaj.org/article/d9456cc4e54044ba8d503456a3f6905c
Autor:
Julie L, Aker, Terry C, Davis, Andrea, Leonard-Segal, Lori, Christman, Sara, Travis, Melissa, Beck, Angela, Newton
Publikováno v:
Journal of General Internal Medicine. 37:2834-2839
Autor:
Gloria Diab, George I. Macrinici, Carol Murphy, Lori Christman, Brittany Hughes, Victor Macrinici, Michelle Drescher
Publikováno v:
Regional Anesthesia and Pain Medicine. 42:10-16
Despite multiple clinical trials comparing the adductor canal block (ACB) with femoral nerve block (FNB) for total knee arthroplasty, none looked at the aforementioned nerve blocks from early functional results to up to 6 months after surgery.For thi
Autor:
Jonathan S. Zager, Christopher A. Puleo, Anne M. Wallace, Julian A. Kim, Vernon K. Sondak, Schlomo Schneebaum, Dennis King, Lori Christman, Steve R. Martinez, Mark B. Faries, Jane L. Messina, Stanley P. L. Leong, Bruce J. Averbook
Publikováno v:
Annals of Surgical Oncology
Background [99mTc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [99mTc]tilmanocept to vital blue dye. Methods Patients
Autor:
Marcus T. Joy, David R. Vera, Dennis King, Lori Christman, Wendy Metz, Bonnie Chandler Abbruzzese, Anne M. Wallace, Richard Hartman, Christopher Tokin, Frederick Cope, Michael Blue, Beth Potter
Publikováno v:
Clinical & Experimental Metastasis. 29:681-686
Sentinel lymph node (SLN) mapping is common, however question remains as to what the ideal imaging agent is and how such an agent might provide reliable and stable localization of SLNs. 99mTc-labeled nanocolloid human serum albumin (Nanocoll®) is th
Publikováno v:
American journal of cancer research. 2(5)
Our purpose is to develop a serum assay to determine an individual’s probability of having colorectal cancer (CRC). We have discovered a protein panel yielding encouraging, clinically significant results. We evaluated 431 serum samples from donors
Autor:
D. King, F. Cope, M.T. Joy, J. Shuping, W. Metz, Richard Hartman, B. Abbruzzese, B. Potter, Lori Christman
Publikováno v:
European Journal of Cancer. 48:64
Autor:
Wendy Metz, Beth Potter, Lori Christman, Jo Shuping, Michael Blue, Frederick Cope, Dennis King, Bonnie Chandler Abbruzzese
Publikováno v:
Journal of Clinical Oncology. 30:e21066-e21066
e21066 Background: ILM is a key diagnostic component for solid tumor excision. ILM utilizes the injection of a color agent and/or a radiopharmaceutical agent (RPA) which may be tracked intraoperatively w/ a γ-probe. ILM is designed to aid the surgeo
Autor:
Michael Blue, Richard Hartman, Jo Shuping, Dennis King, Frederick Cope, Wendy Metz, Lori Christman, Bonnie Chandler Abbruzzese
Publikováno v:
Cancer Research. 72:LB-216
Purpose: Tilmanocept is wholly synthetic molecule composed of a dextran-10 backbone with both multiple mannose side moieties (for receptor biding) and DTPA (for chelation of divalent cations). Tilmanocept is designed as a high affinity ligand for the
Autor:
Linda K. Han, Mark B. Faries, Charles E. Cox, Kenneth B. Deck, Anne M. Wallace, David R. Vera, Dennis King, Eli Avisar, Helen Krontiras, Lori Christman, Schlomo Schneebaum, Carl K. Hoh, Nathan Hall, Thomas G. Frazier, Stephen P. Povoski, Karl K. Limmer
Publikováno v:
Annals of surgical oncology, vol 20, iss 8
Annals of Surgical Oncology
Annals of Surgical Oncology
BackgroundSentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [(99m)Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrando